Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Defence Therapeutics Inc (OP: DTCFF ) 0.5200 UNCHANGED Streaming Delayed Price Updated: 11:18 AM EDT, Aug 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.5200 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.5200 Today's Range 0.5200 - 0.5200 52wk Range 0.5200 - 2.500 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors November 14, 2023 (November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in Via PressReach Exposures Product Safety Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030 November 14, 2023 EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END Via FinancialNewsMedia Performance YTD -68.29% -68.29% 1 Month -21.30% -21.30% 3 Month -42.49% -42.49% 6 Month -64.19% -64.19% 1 Year -75.36% -75.36% More News Read More Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology November 07, 2023 Via PressReach Topics Intellectual Property Exposures Intellectual Property Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 October 25, 2023 Via FinancialNewsMedia Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer October 18, 2023 Via PressReach Exposures Product Safety Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race October 17, 2023 Via PressReach Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race October 10, 2023 Via PressReach Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science October 10, 2023 Via PressReach Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines September 26, 2023 Via PressReach BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment May 10, 2023 Via Newsfile BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News May 04, 2023 Via Newsfile Topics Supply Chain Exposures Supply Chain Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market September 29, 2022 Via Newsfile Topics Death Intellectual Property Exposures Death Intellectual Property Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma September 21, 2022 Via Newsfile Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative September 16, 2022 Via Newsfile Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF) October 19, 2021 Via AB Newswire Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF) October 12, 2021 Via AB Newswire Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF) October 05, 2021 Via AB Newswire Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF) September 28, 2021 Via AB Newswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.